Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$42.25+0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HRMY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks HRMY against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue strong commercial execution to reach full-year WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
Stated as a priority in 4 recent disclosures including 2026-Q2, Q1, and 2025-Q4. Q2 2026 net revenue grew 30% YoY to $261.3M, supporting the trajectory toward the reiterated full-year guidance of $1.0B to $1.04B. The company is delivering sustained growth consistent with management's stated revenue target.
“WAKIX net revenue grew 30% YoY to $261.3M; on track to achieve full-year guidance of $1.0B to $1.04B.”
“Q1 2026 revenue of $215.4M, 17% YoY growth; on track for full year net revenues over $1 billion.”
“Reiterates 2026 net revenue guidance of over $1 billion; 2025 net revenue was $868.5M.”
Maintain strong intellectual property protection and exclusivity for pitolisant, including settlements and patent filings extending exclusivity into the 2040s.
Stated as a priority in 3 quarters including 2026-Q1, 2025-Q4, and 2025-Q3. Management highlights multi-layered IP protection securing exclusivity through March 2030 and patent filings extending protection into the 2040s. The company has settled 6 of 7 ANDA filers, reinforcing its IP defense. The trajectory shows consistent focus on franchise protection.
Progress clinical development of BP-205 as a potential best-in-class orexin-2 agonist and EPX-100 in Phase 3 trials for rare epilepsies.
Stated in 3 quarters including 2026-Q2, Q1, and 2025-Q4. BP-205 has reported favorable Phase 1 data and plans Phase 2 studies mid-2027. EPX-100 is actively enrolling in Phase 3 trials with topline data expected in 1H 2027. Management is advancing the pipeline steadily with clinical milestones approaching.
“BP-205 Phase 1 SAD data demonstrate favorable PK and safety; Phase 2 studies to start mid-2027.”
Prioritize strategic business development targeting assets with revenue potential in the 2028-2032 timeframe.
Stated in 2 quarters including 2026-Q1 and 2025-Q4. Management is prioritizing business development targeting late-stage or marketed assets with revenue potential in 2028-2032. The company maintains a strong liquidity position to support these efforts. The focus is consistent but delivery on specific deals is not detailed.
“Renewed focus on business development with goal to transact on opportunities with revenue potential in 2028-2032 timeframe.”
Maintain strong intellectual property protection for pitolisant to ensure exclusivity into 2030 and extend franchise into the 2040s with new patents and formulations.
Over the trailing year it converted 1.19x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“Harmony's pitolisant IP estate supports exclusivity into 2030 with potential protection into the 2040s via additional patents.”
“Recently completed settlements with 3 additional generic filers, total 6 of 7 settled; strong IP protection for pitolisant.”
“Harmony's pitolisant IP estate is multi-layered and supports WAKIX exclusivity into 2030, with potential extension into the 2040s.”
“BP-205 is a potential best-in-class orexin-2 agonist; Phase 1 SAD/MAD ongoing; clinical PK data expected mid-2026.”
“EPX-100 enrolling in Phase 3 trials for Dravet and Lennox-Gastaut syndromes; topline data expected 1H 2027.”
“Focused on business development opportunities with revenue potential in 2028-2032; prioritizing assets in Phase 3 or on market.”